Sean Lybrand, Executive Director, Access to Healthcare at Amgen, shared a post on LinkedIn:
“International Federation of Pharmaceutical Manufacturers and Associations – Always Innovating!
Amgen Italia is a proud member of IFPMA and as a company we’re driven by the impact of our innovations, and what they mean to health and outcomes.
Members of my family and extended network have been impacted not only by Amgen medicines, but by the medicines our industry develops. I see the impact of our medicines, and others, in hospitals across low- and middle-income countries throughout the year.
As someone who has spent most of my pharmaceutical career in access or policy roles, I’ve spent a lot of time talking about – and advocating for – medicines as an investment in health systems, and not simply a cost. Even in lower-resource settings, medicines need to be considered as an investment in building healthy and productive populations.
Since the 1990s – when I first went to university – pharmaceutical innovation has contributed to more than 70% of gains in life expectancy around the world. In the past 10 years, almost 400 cancer treatments have been approved, revolutionising cancer care, extending and improving lives.
With over 9,600 medicines for chronic diseases – including over 4,700 for cancer – in clinical development today, continued progress depends on strong health systems and policies that enable innovation to reach people.
As Co‑Chair of the Health Progress Working Group at IFPMA, I’m proud to support the Always Innovating campaign and the shared work to improve lives, strengthen health systems, and unlock long‑term social and economic value.”
Other articles featuring Sean Lybrand on OncoDaily.